|1.||O'Connor, Owen A: 11 articles (05/2015 - 02/2006)|
|2.||Zain, Jasmine M: 6 articles (05/2012 - 06/2009)|
|3.||Sirotnak, F M: 5 articles (11/2011 - 09/2000)|
|4.||Azzoli, Christopher G: 4 articles (06/2012 - 05/2006)|
|5.||Kris, Mark G: 4 articles (11/2011 - 05/2006)|
|6.||Krug, Lee M: 4 articles (11/2011 - 05/2006)|
|7.||Duvic, Madeleine: 3 articles (08/2014 - 03/2008)|
|8.||Goldman, I David: 3 articles (05/2014 - 09/2013)|
|9.||Foss, Francine: 3 articles (01/2013 - 05/2012)|
|10.||Koutsoukos, Tony: 3 articles (08/2012 - 05/2012)|
|1.||Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)
07/01/2008 - "Because of the limited therapies available for peripheral T-cell lymphoma, pralatrexate could have a secure niche for the treatment of this indication, if ongoing clinical trials and future phase III trials confirm the efficacy of the drug. "
08/01/2012 - "Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma."
01/01/2012 - "Safety and efficacy of pralatrexate in the management of relapsed or refractory peripheral T-cell lymphoma."
08/01/2012 - "In the Pralatrexate in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PROPEL) study, 12 patients with tMF were treated with a median of 10 pralatrexate doses (starting dose of 30 mg/m(2)) administered weekly for 6 weeks in a 7-week cycle. "
03/20/2011 - "Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study."
|2.||T-Cell Lymphoma (Lymphoma, T Cell)
03/01/2013 - "This paper discusses the pharmacokinetics and efficacy of pralatrexate in T-cell lymphoma in clinical trials. "
04/01/2009 - "Because of the limited therapies available for aggressive T-cell lymphoma, pralatrexate could secure a niche for the treatment of this condition, provided on going clinical trials and future phase III trials confirm the efficacy of the drug."
09/01/2011 - "Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma."
03/01/2013 - "Currently, the potential synergy between pralatrexate and other agents in T-cell lymphoma is being explored in a number of studies. "
09/01/2011 - "Pralatrexate has significant activity in vitro, and in early Phase I/II trials, responses were noted in patients with aggressive T-cell lymphomas. "
09/10/2009 - "To determine the maximum-tolerated dose (MTD) and efficacy of pralatrexate in patients with lymphoma. "
01/01/2013 - "In both preclinical and clinical studies, pralatrexate demonstrated activity in lymphoma. "
01/01/2011 - "This article reviews the biochemistry, preclinical experience, metabolism, and pharmacokinetics of pralatrexate, including the clinical experience with this agent in lymphoma. "
11/01/2009 - "FDA approves pralatrexate for treatment of rare lymphoma."
08/01/2012 - "This review describes the preclinical development of pralatrexate that led to early-phase clinical trials in lung cancer and lymphoma and its subsequent approval in PTCL. "
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
02/01/2010 - "Pralatrexate (PDX, 10-propargyl 10-deazaaminopterin) is an exciting new chemotherapeutic agent with promising activity in T-cell lymphomas and non-small cell lung cancer. "
11/01/2011 - "Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial."
11/01/2011 - "Pralatrexate 135 to 150 mg/m(2) every 2 weeks without vitamin supplementation was active in non-small cell lung cancer (NSCLC) although mucositis was dose limiting. "
04/01/2007 - "The dihydrofolate reductase inhibitor, pralatrexate, has a favorable toxicity profile, primarily limited to stomatitis, and has demonstrated activity in patients with non-small cell lung cancer. "
05/01/2007 - "Pralatrexate (120 mg/m(2)) plus docetaxel (35 mg/m(2)) plus vitamin supplementation is well tolerated with signs of efficacy against non-small-cell lung cancer that merit phase 2 testing."
08/01/2012 - "Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study."
08/01/2014 - "This study aimed to assess the long-term tolerability of pralatrexate alone or in combination with oral bexarotene for relapsed or refractory mycosis fungoides (MF). "
08/01/2014 - "Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides."
10/01/2015 - "This article reviews methotrexate and the more potent, related compound, pralatrexate, for the treatment of cutaneous T-cell lymphomas, including mycosis fungoides, Sézary syndrome, and CD30+ lymphoproliferative disorders. "
11/01/2013 - "Pralatrexate (PDX) is a novel antifolate with a higher affinity for tumor cells than methotrexate, Food and Drug Administration (FDA) approved for use in relapsed and refractory peripheral T-cell lymphoma (PTCL) and transformed mycosis fungoides (T-MF). "
|3.||Folic Acid (Vitamin M)
|4.||Reduced Folate Carrier Protein
|5.||Vitamin B 12 (Cyanocobalamin)
|6.||Folic Acid Antagonists
|9.||erlotinib (CP 358,774)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)